Genotype and Allele Frequency of *CYP3A4 -392A>G* in Turkish patients with major depressive disorder

Majör Depresif Bozukluğu Olan Türk hastalarında *CYP3A4 -392A>G* Genotip ve Alel Frekansı

***CYP3A4 -392A>G* and Major Depressive Disorder**

CYP3A4 -392A>G ve Majör Depresif Bozukluk

ABSTRACT

Objectives: Genetic polymorphisms may help for individualized drug dosing and improved therapeutics. CYP3A4 is responsible for the metabolism of more than 50% of the commonly used drugs and metabolizes typical antipsychotic medications and antidepressant drugs. The objective of the study was to assess the genotype and allele frequencies of *CYP3A4 -392A>G* in Turkish patients with major depressive disorder receiving any selective serotonin reuptake inhibitors and compare these results with the frequencies of other ethnic groups.

Materials and Methods: Genotyping analyses of *CYP3A4 -392A>G* was conducted on 84 Turkish patients by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique.

Results: The allele frequencies were found to be 0.982 (A) and 0.018 (G) for *CYP3A4 -392A>G*. The genotype frequencies were determined to be 0.976 (AA), 0.012 (AG), and 0.012 (GG). The genotype frequencies were consistent with Hardy–Weinberg equilibrium.

Conclusion: The genotype and allele frequencies of *CYP3A4 -392A>G* were determined to be low in Turkish patients with major depressive disorder receiving selective serotonin reuptake inhibitors. Furthermore, the results of the study were compared with those of other ethnic groups, and they displayed pronounced differences among other ethnic groups, especially the black subjects.

Key words: *CYP3A4 -392A>G*, Polymorphism, Turkish, Major depressive disorder

ÖZ

Amaç: Genetik polimorfizmler, bireyselleştirilmiş ilaç dozlaması ve geliştirilmiş terapötikler için yardımcı olabilir. CYP3A4 yaygın olarak kullanılan ilaçların % 50'sinden fazlasının metabolizmasından sorumludur ve tipik olarak antipsikotik ilaçlar, antidepresan ilaçları metabolize eder. Çalışmanın amacı, herhangi bir seçici serotonin geri alım inhibitörü alan majör depresif bozukluğu (MDB) olan Türk hastalarında *CYP3A4 -392A>G* genotip ve alel frekanslarını değerlendirmek ve sonuçları diğer etnik grupların frekansları ile kıyaslamaktır.

Gereç ve Yöntemler: *CYP3A4 -392A>G*'nin genotiplendirme analizi, 84 Türk hastasında polimeraz zincir reaksiyonu- restriksiyon fragman uzunluk polimorfizmi (PZR-RFLP) tekniği ile gerçekleştirilmiştir.

Bulgular: *CYP3A4 -392A>G* için allel frekanslarının 0.982 (A) ve 0.018 (G) olduğu saptanmıştır. Genotip frekanslarının ise 0.976 (AA), 0.012 (AG) ve 0.012 (GG) olduğu tespit edilmiştir. Genotip frekansları Hardy-Weinberg dengesiyle uyumludur.

Sonuç: Seçici serotonin geri alım inhibitörü alan major depresif bozukluğu olan Türk hastalarında *CYP3A4 -392A>G* genotip ve alel frekansının düşük olduğu belirlenmiştir. Bunun yanı sıra, çalışmanın sonuçları diğer etnik grupların frekansları ile kıyaslanmış olup diğer etnik gruplar arasında, özellikle siyah deneklerde, belirgin farklılıklar gözlenmiştir.

Anahtar kelimeler: *CYP3A4 -392A>G,* polimorfizm, Türk, Major depresif bozukluk

INTRODUCTION

Cytochrome P450 (CYP) is the major metabolizing enzymatic system in humans and the CYP enzymes are responsible for metabolism of exogenous compounds, including most clinically used drugs, mutagens, carcinogens[1,2], and some endogenous compounds, such as prostaglandins, steroids, vitamins, fatty acid derivatives and retinoic acid derivatives, thromboxanes.[2,3] The CYP enzymes are responsible for the biotransformation of lipophilic compounds to polar metabolites, which can be excreted by the urine or bile. There are three major CYP families that encode enzymes that play an important role in phase I metabolism: CYP1, CYP2, and CYP3.[3] The CYP3A subfamily is the most abundant CYP enzyme and represents about 30% of the total CYP in the human liver.[2] Approximately 65% of current drugs used are metabolized by CYP enzymes and 45-60% of clinically administered drugs, exogenous and endogenous compounds such as streoids are metabolized by the CYP3A subfamily.[4,5] The CYP3A subfamily consists of 4 members: *CYP3A4*, *CYP3A5*, *CYP3A7* and *CYP3A43*.[5] The CYP3A4 enzyme is the most abundant CYP isoform in liver and intestine, representing 60% and 70% of the total P450 amount, respectively. CYP3A4 is responsible for the metabolism of more than 50% of the commonly prescribed drugs and metabolizes typical antipsychotic medications, antidepressant drugs (Table 1). Its interindividual hepatic expression varies 60-fold, resulting in therapeutic failure, unpredictable adverse side effects or severe drug toxicity.[6]

The *CYP3A4* gene is located on chromosome 7q21.3-q22.1, is 27,592 base pairs (bp) long, and has 13 exons.[3,7] Genetic polymorphisms of *CYP3A4* were unknown until 1996.[7] However, nowadays *CYP3A4* is known to be polymorphic, and more than 30 single nucleotide polymorphisms have been described in the *CYP3A4* gene. The most common single-nucleotide polymorphism *-392A>G* in the promoter region of *CYP3A4* gene has been described. *CYP3A4 -392A>G* (rs2740574) is also known as *CYP3A4*1B*. It is known that *CYP3A4*1B* polymorphism alter the transcription efficiency of gene and hence the overall activity of CYP3A4 enzyme.[8]

The selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for mild to severe major depressive disorder (MDD).[10] The objective of this study was to assess

the genotypic and allelic frequencies of the *CYP3A4*1B* in Turkish patients with MDD receiving SSRIs and compare the results with the frequencies in other ethnic groups.

MATERIALS AND METHODS

Subjects

The study was conducted on 84 Turkish patients with MDD at the Departments of Psychiatry, Schools of Medicine, Ankara University and Kırıkkale University, Turkey. All participants were administered with selective serotonin reuptake inhibitors (SSRIs). Approval of this study was obtained from the ethics committees of the Ankara University (21 April 2008, protocol no: 128-3581). The study was conducted in accordance with Good Clinical Practices and the Helsinki declaration. All of the subjects gave their written informed consent to participate in this study. Demographic data of the MDD patients are shown in Table 2.

Blood sampling

Blood samples (10 mL) were collected in vacutainer tubes containing EDTA as anticoagulant between 08:00 and 09:00 a.m. at the 4th and/or 6th weeks of treatment. The Wizard Genomic DNA Purification Kit (Promega) was used to isolate genomic DNA from the cell fraction. DNA yields were determined by measuring the absorbance at 260 nm (A_{260}). All samples were stored at -80°C until analysis.

Genotyping

The *CYP3A4*1B* (rs 2740574; *-392A>G*) polymorphism was identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method according to Cavalli et al.[11] with minor modifications. The primers employed were F: 5'-GGAATGAGGACAGCCATAGAGACAAGGGGA-3', R: 5'CCTTTCAGCTCTGTGTTGCTCTTTGCTG-3'. PCR was performed in a 25-µl reaction mixture containig 300-500 ng of genomic DNA, 10 pmol of each primer, 0.2 mM each deoxynucleotidetriphosphate, 10 x PCR buffer, 1.5 mM $MgCl_2$, and 1.25 unit of Taq polymerase (Fermentase) on the MBS Satellite Thermal Cycler (Thermo, UK). After initial denaturation for 5 min at 97 ˚C, the PCR was performed for 30 cycles of 60 s at 95 ˚C, 90 s at 60 ˚C, 60 s at 72 ˚C with a final step of 72 ˚C for 10 min for elongation. No added DNA (negative control) reactions were included in each PCR analysis to ensure there agents used that contained no contaminating DNA. The PCR product

(385 bp) was analyzed electrophoretically on a 2 % agarose gel stained with ethidium bromide (500 ng/ml). 10 μl of the PCR product was digested at 37°C overnight with 10 U of *MboII* with the appropriate buffer in total volume of 20 μl. The digestion resulted in fragments of 175, 169 and 41 bp for the A allele, and fragments of 210 and 175 bp for the G allele. The digested fragments were electrophoresed on a 2% agarose gel and visualized using ethidium bromide.

Statistical analysis

Genotype counting method was used to calculate allele and genotype frequencies. The observed and expected genotype frequencies of CYP3A4 were compared with Hardy–Weinberg equilibrium. The comparison of the allele frequencies in the present investigation with those in other populations was used through chi-square test. A *P* value <0.05 and <0.001 were considered statistically significant.

RESULTS

The *CYP3A4*1B* (-392A>G) polymorphism analysis was conducted on 84 Turkish patients with MDD. Of the eighty-four patients, 68 (81% of patients) were female, whereas 16 (19% of them) were male (*P>0.05*) (Table 2). The body weight of the employed patients varied from 45.5 to 105 kg, with a mean of 70.12 ± 14.39 kg. The body mass index of the patients (BMI) ranged from 16.1 to 41.14 kg/m^2, with a mean of 25.94 ± 5.14 kg/m^2. In the study, 53 subjects (63%) were ≤40 years of age, but 31 subjects (37%) were >40 years of age.

The frequencies of the *AA*, *AG*, and *GG* genotypes were 0.976, 0.012 and 0.012 respectively. According to these results, the frequencies of *A* and *G* alleles were 0.982 and 0.018, respectively (Table 2). These results were consistent with the expected genotype frequencies of the Hardy–Weinberg equilibrium (*P>0.05*).

DISCUSSION

The factors that can influence the response of a patient to any given drug depend on intrinsic (genetic and non-genetic factors such as gender, age, organ dysfunctions, disease state and race/ethnicity etc.) and extrinsic factors (use of alcohol, smoking, diet and concomitant medications etc.).[12,13] Genetics is estimated to account for 20 to

95 % of variability in drug effects and disposition.[14] It has been shown that much of this variability has been produced by genetic polymorphisms of the CYP enzymes.[4] CYP enzymes perform extensive structural differences because of genetic polymorphisms in the corresponding genes, and thus causing differrent enzymatic activities and giving rise to great intra- and inter-population variation in drug efficacy and adverse reactions.[15]

Approximately 65% of current drugs used are metabolized by CYP enzymes, and 45-60% of clinically administered drugs, exogenous and endogenous compounds such as streoids are metabolized by the CYP3A subfamily.[4,5] CYP3A4 is a polymorphic enzyme, and its interindividual hepatic expression varies 60-fold.[6] *CYP3A4*1B* described as the most common variant has been speculated to have a reduced activity.[16] Significant differences in allele frequencies of CYP3A variant occur among ethnic groups.[16] Polymorphisms in human xenobiotic metabolizing genes show parallelism in ethnical, racial and geographical distribution, and the ethnic-specific impact on CYP genes is known.[8]

In this study, we aimed to investigate the *CYP3A4*1B* allele frequencies in Turkish patients with MDD receiving SSRIs and compare the results with the frequencies of other ethnic groups. The allele frequencies in Turkish population were 0.982 and 0.018 for *1A* and *1B* alleles, respectively (Table 3). A comparison of the results of this investigation with the results of the other studies is presented in Table 3. Sayitoglu et al. reported that *1B* allele frequency was 0.014 in healthy Turkish subjects.[16] Doğruer et al. reported that *1B* allele frequency was 0.033 in Turkish patients with Familial Mediterranean fever.[17] Gurocak et al. also reported that *1B* allele frequency was 0.044 and 0.061 for Turkish children with lower urinary tract symptoms and healthy Turkish children, respectively.[18] The allele frequencies of these studies were not significantly different from the results of this study (*P>0.05*). However, when compared to black subjects, the allele frequency of Turkish subjects showed marked differences. The *1B* variant allele frequencies were identified more frequently in African-American, African Brazilians, African, Ghanaian when compared to the Turkish subjects (*P<0.001*). Furthermore, the *1B* variant allele frequencies were also reported to be higher in Caucasian American (Philadelphia), Saudi, European-Brazilians, Hispanic populations when compared to the Turkish populations (*P<0.05*). The distribution of *1A* and *1B*

alleles in Turkish populations was similar to those reported for Caucasians (Germany), Australian, European, Finnish, Spanish, Portuguese, Caucasians American (Southern California), Ducth Caucasian, and Scottish (Table 3).

The allelic frequency of *CYP3A4*1B* changes among different ethnic groups; *CYP3A4*1B* allelic frequency is dominant in black subjects with range of 38.4 to 82.4% (Table 3); On the other hand, this polymorphism is very rare in Asian ethnic groups, including Vietnamese and Jordanian, ranging of 0 to 9.0%. This polymorphism is absent in East Asian populations including Japanese, Chinese, and Taiwanese and present in White ethnic groups with range of 1.8 to 14.3%. Consequently, it seems that *CYP3A4*1B* polymorphism is higher in White ethnic groups compared to East Asian populations, and is much higher in black subjects compared to White ethnic groups. There is minimal clinical effect of *CYP3A4*1B* polymorphism on Asian ethnic groups. On the other hand, *CYP3A4*1B* polymorphism seem to be clinically more important in black subjects.

CONCLUSION

In conclusion, the study introduces evidence of low-frequency *CYP3A4*1B* allele in the Turkish patients and comparison this frequency with the frequency of other ethnic groups. Given the effect of CYP3A4 on the efficacy of drugs, the genetic backgrounds of individuals and populations are accepted as a significant factor to be considered in the recipe of individualized medicine.[19] To figure out the expression of CYP3A4 may detect drug safety and efficacy, therefore helping people use the right dose of the drugs.[15] *CYP3A4*1B* should be taken into consideration in populations where the allele frequency is high. On the other hand, a larger sample size should be needed to determine the *CYP3A4*1B* polymorphism in populations where the allele frequency is low.

REFERENCES

1. Ota T, Kamada Y, Hayashida M, Iwao-Koizumi K, Murata S, Kinoshita K. Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population. Int J Med Sci. 2015;12:78-82.

2. Ruzilawati AB, Suhaimi AW, Gan SH. Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. Clin Chim Acta. 2007;383:158-162.

3. Nogal A, Coelho A, Catarino R, Morais A, Lobo F, Medeiros R. The CYP3A4 *1B* polymorphism and prostate cancer susceptibility in a Portuguese population. Cancer Genet Cytogenet. 2007;177:149-152.

4. Maruf AA, Ahmed MU, Azad MA, Ahmed M, Hasnat A. CYP3A genotypes in Bangladeshi tuberculosis patients. Bangladesh Med Res Counc Bull. 2012;38:1-5.

5. Salameh G, Al Hadidi K, El Khateeb M. Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population. Environ Toxicol Pharmacol. 2012;34:23-33.

6. Zhou Q, Yu X, Shu C, Cai Y, Gong W, Wang X, Wang DM, Hu S. Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet. 2011;56:415-422.

7. Keshava C, Mccanlıes EC, Weston A. CYP3A4 Polymorphisms- Potential Risk Factors for Breast and Prostate Cancer: A HuGE Review. Am J Epidemiology. 2004;160:825-841.

8. Kumar V, Singh S, Yadav CS, Ahmed RS, Gupta S, Pasha ST, Tripathi AK, Banerjee BD. CYP1A1 and CYP3A4 polymorphic variations in Delhi population of Northern India. Environ Toxicol Pharmacol. 2010;29:126-130.

9. Ayano G. Psychotropic Medications Metabolized by Cytochromes P450 (CYP) 3A4 Enzyme and Relevant Drug Interactions: Review of Articles. Austin J Psychiatry Behav Sci. 2016(id1054);3:1-3.

10. Uckun Z, Baskak B, Ozdemir H, Ozel-Kizil ET, Devrimci Ozguven H, Suzen HS. Association Between the 5-HTTLPR Polymorphism and Response to Citalopram in Turkish Patients with Major Depressive Disorder. Turk J Pharm Sci. 2016;13:145-158.

11. Cavalli SA, Hirata MH, Hirata RD. Detection of MboII polymorphism at the 5' promoter region of CYP3A4. Clin Chem. 2001;47: 348-351.

12. Uckun Z, Baskak B, Ozel-Kizil ET, Ozdemir H, Devrimci Ozguven H, Suzen HS. The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder. J Clin Pharm Ther. 2015;40:672-679.

13. Huang SM, Goodsaid F, Rahman A, Frueh F, Lesko LJ. Application of Pharmacogenomics in Clinical Pharmacology. Toxicol Mech Methods. 2006;16: 89–99.

14. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006;234:4–33.

15. Jin T, Yang H, Zhang J, Yunus Z, Sun Q, Geng T, Chen C, Yang J. Polymorphisms and phenotypic analysis of cytochrome P450 3A4 in the Uygur population in northwest China. Int J Clin Exp Pathol. 2015;8:7083-7091.

16. Sayitoglu MA, Yıldız I, Hatırnaz O, Ozbek U. Common Cytochrome p4503A (CYP3A4 and CYP3A5) and Thiopurine S-Methyl Transferase (TPMT) Polymorphisms In Turkish Population. Turk J Med Sci. 2006;36:11-15.

17. Dogruer D, Tug E, Bes C, Soy M. Lack of an effect of CYP3A4 and MDR1 gene polymorphisms on colchicine pharmacogenetics in the treatment of Familial Mediterranean fever. Genet Mol Res. 2013;12:3521-3528.

18. Gurocak S, Konac E, Ure I, Senol C, Onen IH, Sozen S, Menevse A. The Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder. Dis Markers. 2015;2015:732686.

19. Lee JS, Cheong HS, Kim LH, Kim JO, Seo DW, Kim YH, Chung MW, Han SY, Shin HD. Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes. Korean J Physiol Pharmacol. 2013;17:479-484.

20. Dally H, Bartsch H, Jäger B, Edler L, Schmezer P, Spiegelhalder B, Dienemann H, Drings P, Kayser K, Schulz V, Risch A. Genotype relationships in the CYP3A locus in Caucasians. Cancer Lett. 2004;207:95-99.

21. Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM, McCredie MR, Giles GG, Chenevix-Trench G, Liddle C. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics. 2002;12:355-366.

22. Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet. 2005;6:19.

23. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS. Association between a CYP3A4 Genetic Variant and Clinical Presentation in African-American Prostate Cancer Patients. Cancer Epidemiol Biomarkers Prev. 1999;8:901-905.

24. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 2000;67:48-56.

25. Gervasini G, García-Martín E, Ladero JM, Pizarro R, Sastre J, Martínez C, García M, Diaz-Rubio M, Agúndez JA. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer. 2007;7:118.

26. van Schaik RH, de Wildt SN, van Iperen NM, Uitterlinden AG, van den Anker JN, Lindemans J. CYP3A4-V Polymorphism Detection by PCR-Restriction Fragment Length Polymorphism Analysis and Its Allelic Frequency among 199 Dutch Caucasians. Clin Chem. 2000;46:1834-1836.

27. Tayeb MT, Clark C, Ameyaw MM, Haites NE, Evans DA, Tariq M, Mobarek A, Ofori-Adjei D, McLeod HL. CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics. 2000;10:753-756.

28. Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Jalloh M, McBride S, Deitz A, Malkowicz SB, Ofori-Adjei D, Gueye SM, Rebbeck TR. Ethnic Differences in the Frequency of Prostate Cancer Susceptibility Alleles at SRD5A2 and CYP3A4. Hum Hered. 2002;54:13-21.

29. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4. J Natl Cancer Inst. 1998;90:1225-1229.

30. Kohlrausch FB, Carracedo Á, Hutz MH. Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians. Mol Biol Rep. 2014;41:1453-1460.

31. Walker AH, Jaffe JM, Gunasegaram S, Cummings SA, Huang CS, Chern HD, Olopade OI, Weber BL, Rebbeck TR. Characterization of an allelic variant in the niphedipine-specific element of CYP3A4: Ethnic distribution and implications for prostate cancer risk. Mutation in Brief no. 191. Online. Hum Mutat.1998;12:289.

32. Ando Y, Tateishi T, Sekido Y, Yamamoto T, Satoh T, Hasegawa Y, Kobayashi S, Katsumata Y, Shimokata K, Saito H. Re: Modification of clinical presentation of prostate tumors bya novel genetic variant in CYP3A4. J Natl Cancer Inst. 1999;91:1587-1590.

33. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, Hall J. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther. 1999;66:288-294.

34. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Hanai S, Nakajima T, Matsumoto K, Saito H, Goto Y, Kimura H, Katoh M, Sugai K, Minami N, Shirao K, Tamura T, Yamamoto N, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada J. Haplotypes of CYP3A4 and Their Close Linkage With CYP3A5 Haplotypes in a Japanese Population. Hum Mutat. 2004;23:100.

35. Veiga MI, Asimus S, Ferreira PE, Martins JP, Cavaco I, Ribeiro V, Hai TN, Petzold MG, Björkman A, Ashton M, Gil JP. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol. 2009;65:355-363.

36. Yousef AM, Bulatova NR, Newman W, Hakooz N, Ismail S, Qusa H, Zahran F, Anwar Ababneh N, Hasan F, Zaloom I, Khayat G, Al-Zmili R, Naffa R, Al-Diab O. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep. 2012;39:9423–9433.

37. McDaniel DO, Thurber T, Lewis-Traylor A, Berry C, Barber WH, Zhou X, Bigler S, Vance R. Differential association of cytochrome p450 3a4 genotypes with onsets of breast tumors in african american versus caucasian patients. J Investig Med. 2011;59:1096-1103.

38. Bangsi D, Zhou J, Sun Y, Patel NP, Darga LL, Heilbrun LK, Powell IJ, Severson RK, Everson RB. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol Oncol. 2006;24:21-27.

39. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clin Pharmacol Ther. 2000;68:82-91.

Table 1. Common drugs metabolized by *CYP3A4*[9]

Group of drugs	Drug name
Antidepressants (SSRIs; SNRIs; tricyclics; others)	citalopram, escitalopram, paroxetine, fluoxetine; venalafaxine, trazodone; amitriptyline, imipramine, clomipramine; buspirone nefazodone, mirtazapine
Antipsychotics (first generations; second generations)	haloperidol, perphenazine; aripiprazole, quetiapine, risperidone, ziprasidone
Benzodiazepines	alprazolam, diazepam, medazolam, temazepam, lorazepam, clonazepam
Opiates	codeine, methadone, fentanyl, buprenorphine
Hypnotics	zopiclone, Zaleplon, zolpidem
Antibiotics	erythromycin, clarithromycin, telithromycin
Phosphodiesters (PDEs) inhibitors	sildenafil, tadalafil

Table 2. Baseline characteristics of the patients with major depressive disorder

Demographic&Genotypic characteristics	Mean±SD	Range (mix-max)
Body Weight (kg)	70.12±14.39	45.5 - 105
BMI (kg/m^2)	25.94±5.14	16.1 - 41.14

	n	%
Gender		
Female	68	81
Male	16	19
Age range		
≤40	53	**63**
>40	31	**37**
CYP3A4 **genotypes**		
Genotypic frequencies		
AA (or *1A*1A)*	82	97.6
AG (or *1A*1B)*	1	1.2
GG (or *1B*1B)*	1	1.2
Allelic frequencies		
A (or *1A*)	165	98.6
G (or *1B*)	3	1.8

Table 3. Allele frequencies of *CYP3A4*1B* in different ethnic populations

Population	Healthy and control populations, etc.	n	*1A	*1B	References
White					
Turkish	Healthy	186	0.986	0.014	Sayitoglu et al.[16]
Turkish	Major depressive patients	84	0.982	0.018	The present study
Turkish	Familial Mediterranean fever patients	46	0.967	0.033	Dogruer et al.[17]
Turkish	Children with lower urinary tract symptoms	34	0.956	0.044	Gurocak et al.[18]
Turkish	Healthy children	42	0.939	0.061	Gurocak et al.[18]
Caucasian (Germany)	Hospital controls	428	0.972	0.028	Dally et al.[20]
Australian	Control for ovarian cancer	276	0.969	0.031	Spurdle et al.[21]
Australia	Control for breast cancer	500	0.967	0.033	Spurdle et al.[21]
European	Healthy	93	0.962	0.038	Garsa et al.[22]
Caucasian American (Southern California)	Healthy	117	0.961	0.039	Paris et al.[23]
Finnish	Healthy	118	0.958	0.042	Sata et al.[24]
Spanish	Healthy	163	0.957	0.043	Gervasini et al.[25]
Portuguese	Control	337	0.951	0.049	Nogal et al.[3]
Dutch Caucasian	Healthy	199	0.947	0.053	van Schaik et al.[26]
Scottish	Healthy	101	0.946	0.054	Tayeb et al.[27]
Caucasian American* (Philadelphia)	Controls	340	0.921	0.079	Zeigler-Johnson et al.[28]
Saudi*	Healthy	101	0.910	0.090	Tayeb et al.[27]
Caucasian American* (Philadelphia)	Healthy	94	0.904	0.096	Rebbeck et al.[29]
European-Brazilians*	Healthy	91	0.901	0.099	Kohlrausch et al.[30]
Hispanic*	Controls	121	0.893	0.107	Paris et al.[23]
Asians					
Taiwanese	-	130	1.000	0.000	Walker et al.[31]
Japanese	Healthy	128	1.000	0.000	Ando et al.[32]
Japanese	Healthy	77	1.000	0.000	Ball et al.[33]
Japanese	Hospital patients	416	1.000	0.000	Fukushima et al.[34]
Chinese	Healthy	78	1.000	0.000	Ball et al.[33]
Chinese	Healthy	118	1.000	0.000	Sata et al.[24]
Vietnamese	Healthy	78	0.979	0.021	Veiga et al.[35]
Jordanian	Healthy	173	0.965	0.035	Yousef et al.[36]
Black**					
African-Brazilians	Healthy	86	0.616	0.384	Kohlrausch et al.[30]
African	Controls	67	0.560	0.440	McDaniel et al.[37]
African American	-	70	0.470	0.530	Walker et al.[31]
African American	Healthy	116	0.457	0.543	Paris et al.[23]
African American	Healthy	186	0.454	0.546	Ball et al.[33]
African American	Controls	103	0.427	0.573	Bangsi et al.[38]
African American	Controls	130	0.408	0.592	Zeigler-Johnson et al.[28]
African	Healthy	150	0.333	0.667	Sata et al.[24]
Ghanaian	Healthy	100	0.310	0.690	Tayeb et al.[27]
African American	Healthy	15	0.200	0.800	Wandel et al.[39]
Ghanaian	Controls	118	0.195	0.805	Zeigler-Johnson et al.[28]
African	Healthy	88	0.176	0.824	Garsa et al.[22]

Differences in allele frequencies were assessed by X^2 test. n total number of subjects.
Significant at *$P < 0.05$ and **$P < 0.001$ when compared the present study.

Figure 1. RFLP for the *CYP3A4*1B* polymorphism. Lane M: Marker, Lane 2: mutant (210, 175 bp), Lane 1,3-6: wild type (175, 169, 41 bp).